Health Information Center

Global Weight Loss
and Diet Management (2009 – 2014)

Report description

The global weight management market continues to grow despite the current downturn in the global economy and is estimated to reach US$586 billion in 2014 from about US$363 billion in 2009. The driving force for the global weight management market is the dramatic increase in the obese population. Sedentary but fast paced lifestyle and consumption of high calorie and under-nutritious food has contributed to the rising number of obese and overweight people. These are the main target segment of the weight management market. ( http://www.bharatbook.com/Market-Research-Reports/Global-Weight-Loss-and-Diet-Management.html )

Consumer focus on improving quality of life has increased the sale of products that claim to manage or reduce weight. The existing players in the food and beverage (F&B) market, as well as in the drugs and supplement market, have accordingly expanded their market scope to increase revenues by targeting this segment. Marginal weight loss can be attained through personal efforts, however, overweight and obesity are increasingly becoming a concern that require the intervention of professionals and other service providers. This is expanding the scope of weight management services market.

Continue reading ‘Bharatbook.com : Global Weight Loss and Diet Management’ »

Breast cancer is the second most common type of cancer after lung cancer worldwide and the fifth most common cause of cancer death. It is found more in women as compared to men. Worldwide more than one million new cases of breast cancer are found every year. New breast cancer cases are mostly found in North America.

Breast cancer is usually found in women over the age of 40 years. Breast cancer cases have risen about 30% in the past 25 years in western countries like the US and Europe. Breast cancer market is comprised of two segments – diagnostic and therapy. The key drivers of breast cancer market are aging population, obesity and family history among others. Continue reading ‘New Report "breast Cancer Market – An Analysis" Available Through Aarkstore Enterprise’ »

Pfizer’s novel NGF pain drug is potential game changer

Phase II clinical trials of tanezumab in osteoarthritis, chronic low back pain and interstitial cystitis have demonstrated the drug’s analgesic efficacy across these three chronic pain settings. Despite safety concerns and a high price point, it expects tanezumab to enjoy a significant first-in-class advantage in a potentially lucrative novel area of pain therapy. ( http://www.bharatbook.com/detail.asp?id=130154&rt=Stakeholder-Insight-Osteoarthritis-Drug-development-lags-behind-rising-osteoarthritis-population.html )

Pfizer has announced positive results from three Phase II trials in pain at the American Academy of Pain Medicine’s 26th Annual Meeting. The randomized, double-blind, placebo-controlled six-week trials in patients with chronic low back pain (CLBP) and interstitial cystitis receiving a single intravenous infusion of tanezumab (200mcg/kg) met their primary endpoints of significantly superior pain relief over placebo. Continue reading ‘Pfizer's novel NGF pain drug is potential game changer’ »

Oncology Market Leaders – Analyses and Outlook – 2010-2025

Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WHO). Furthermore, anti-cancer drug sales exceeded $50bn worldwide in 2009. The oncology drug market has grown impressively, driven by rising disease prevalence, expanding patient populations and technological advances, especially in biomolecular medicine. Current treatments are better-tolerated, more- effective and more-commercially-successful than ever before, our latest report shows. ( http://www.bharatbook.com/detail.asp?id=132312&rt=Oncology-Market-Leaders-Analyses-and-Outlook-2010-2025.html )

The aging of populations, lifestyle changes in the developing world, together with significant advances in pharmacotherapy and diagnostics, will drive the cancer treatments market from 2010 onwards. Increasing disease prevalence and a strong R&D pipeline make the anti-cancer sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report, Oncology Market Leaders – Analyses and Outlook – 2010-2025, explains why and to what extent, revealing where the most-exciting and lucrative developments will lie from 2010 onwards. There, you will find detailed sales predictions and supporting discussions. Continue reading ‘Comprehensive Analysis Of The Oncology Market Sector’ »

There has always been a cure for cancer but our doctors and research scientists don’t know about it. The cure is exactly the same as its prevention, which is a lifestyle that enhances the immune system. So why aren’t we told this or why are we still searching for a cure? It’s because profit plays a huge role in all western medicine whereas nature cannot be patented so there’s no profit in conducting studies on natural remedies for cancer. The potential as a money-maker using a drug to cure cancer is enormous and that’s why they are still looking.

Cancer is a deficiency disease where the body has been weakened by the way we live with our wrong food choices, our sedentary lifestyle and other factors and there isn’t a drug to cure that problem. There are only natural ways to achieve that by correcting the factors that first caused it. That’s why they haven’t been able to find a cure for cancer because what they are looking for doesn’t exist.

This is history repeating itself. In the last 2 or 3 hundred years there have been diseases such as scurvy, pellagra, pernicious anaemia and rickets which are also deficiency diseases and it took decades for doctors to realize this. Even when the causes were found they were very slow in implementing the changes necessary to bring these diseases under control. Continue reading ‘We Already Have A Cure For Cancer So Why Are We Still Funding Research’ »

EASD 2009: Lantus defended amid allegations of increased cancer risk

It presenters at the conference discussed the current evidence and its limitations. However, a potential mechanism by which insulin could promote cancer cell growth was also proposed. ( http://www.bharatbook.com/detail.asp?id=91847&rt=Commercial-Insight-Cardiovascular-and-Metabolic-Market-Overview-Diabetes-to-the-fore-as-generics-hit-primary-care-markets.html )

Although the European Association for the Study of Diabetes (EASD) recommended the continued use of Lantus in type 1 and type 2 diabetics, it has called for increased research into the relationship between insulin therapy – particularly Lantus (insulin glargine; Sanofi-Aventis) – and the risk of cancer.

It was postulated during the discussion at the 2009 EASD meeting that insulin use may be related to the increased incidence of cancer seen in diabetics over that seen in the general population. The preliminary data discussed in the symposium suggested lower rates of cancer with Levemir (insulin detemir; Novo Nordisk) compared to neutral protamine Hagedorn (NPH), but higher rates with Lantus. Continue reading ‘EASD 2009 – Lantus defended amid allegations of increased cancer risk’ »

The US department of energy announced massive investment the renewable industry including $60bn in clean energy investments, which will include $11bn in a smart grid system, $2bn in developing the next generation of energy storage batteries. An announced move away from corn-based ethanol fuel and $1.8bn investment in the next generation of biofuels will stimulate the vehicular fuel industry, towards a cleaner, more efficient system. The new administration has announced intention to develop available offshore renewable energy source located on the continental shelf area. The area has vast potential and scientists estimate that 900GW of wind power may be achieved.

Although still primarily a conventional thermal based country, through incentivized support in renewable energy, a new energy market is beginning to evolve. Recent addition has been made to the energy mix by way of renewable energy technologies which include power from the wind – wind turbines, and power from the sun – solar cells, and geothermal – relying on the heat that can be found at varying degrees of depth into the Earth’s surface. In the last decade newly installed renewable energy technologies are starting to gain a notable share of the market. This report documents the growth of this new market, showing its current status and projecting where it is likely to grow to in the foreseeable future. This document gathers the statistical data on the different types of energy generation, combines and contrasts them against each other to show the clear leaders, drivers to change and future growth. Continue reading ‘The Diabetes Market Outlook To 2014: Market Dynamics, Competitive Landscape, Emerging Therapies-Aarkstore Enterprise’ »

Global healthcare market is evolving from traditional healthcare system to modern healthcare system of E-health which minimizes the physical movement of patients and enhances the coverage of healthcare services. As the world population is aging, it has resulted in increase of global healthcare expenditure. The major increase in healthcare expenditure is being witnessed in developed nations where population is ageing at a higher pace compared to less developed nations. Aging population has resulted in increase in demand of healthcare services which is already in an over-pressurized state.

It is now believed that telemedicine is going to be an important component of the modern healthcare system which will ease the pressure over the existing healthcare system which is suffering from problems like lack of required number of physicians, high cost and limited reach in the rural areas. Telemedicine, being a component of E-health, is a provision of healthcare services that uses telecommunication technology and multimedia equipment to provide healthcare solutions over a geographic distance. Continue reading ‘New Report "analysis Of Telemedicine Market" Available Through Aarkstore Enterprise’ »

Axcan Pharma Inc.-Company Report provides up to date insight into the structure and operations of privately-held pharmaceutical, biotechnology and biomedical companies.

Scope of the reports

Accessing accurate, current and comprehensive content on private companies can be challenging and Life Science Analytics has created a suite of reports that deliver the latest information on over 1,000 private firms. Each report provides a corporate overview and business description along with detail on the company’s management team and its products. . Continue reading ‘Axcan Pharma Inc.-Company Report’ »

New England Journal of Medicine recently published a study affirming Fosamax’s tendency to cause sudden, low-energy femur fracture to long-time users of the biphosphonate drug, a revelation affecting many osteoporosis patients which concerns the doctors treating them. The medical world was divided relating to the Fosamax study recently published. While there were physicians who were undeterred by the said Fosamax study, there were other doctors who were not happy with the issue. Dr. Kenneth Egol, an orthopedic surgery professor hailing from New York University, examined radiographic results of patients claiming they got the fracture injury due to Fosamax drug use.

Fosamax are presently not prescribed by medical practitioners who has been assessed to having low body mass indexes, history of falls, and is known to have smoking and drinking habits in light of the rising claims against Fosamax’s adverse effects. “If a person is diagnosed with osteoporosis and it’s decided they should be treated with bisphosphonates, they should try the medications.” shared by Dr. Ken Lyles of Duke University on his thoughts in light of the study recently published.

Continue reading ‘Opposing Thoughts by Physicians About Fosamax Femur Fracture Research’ »